Medicenna Therapeutics Corp.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Medicenna Therapeutics Corp., founded in 2015 and headquartered in Toronto, Canada, is a clinical-stage immunotherapy company focused on the development of highly selective Superkines targeting cancer, autoimmune diseases and inflammatory diseases. The company’s core pipeline includes MDNA11, a long-acting IL-2 Superkine being evaluated in the Phase 1/2 ABILITY-1 study in monotherapy and combination with pembrolizumab for advanced solid tumors; MDNA113, a first-in-class tumor-anchored and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine advancing through IND-enabling work for solid tumors; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine being advanced for recurrent glioblastoma and other brain cancers. Medicenna’s platform technologies include BiSKITs and T-MASK, which are used to design targeted and masked immunotherapies intended to widen the therapeutic window and improve tumor selectivity. The company’s programs are directed primarily at difficult-to-treat cancers, including melanoma, endometrial cancer, gastrointestinal cancers and glioblastoma, with development efforts centered in Canada and the United States and supported by global clinical and partnering activities. In 2026, Medicenna reported continued clinical progress for MDNA11, including updated response data supporting advancement toward a potential registrational strategy, and expanded earlier-line development through the Fondazione Melanoma-sponsored NEO-CYT trial in resectable high-risk melanoma. The company also advanced MDNA113 with new preclinical data from non-human primate studies, issued plans to file an IND and begin first-in-human testing in late 2026, and strengthened its intellectual property estate with new issued and allowed patents across its IL-2, IL-4 and IL-13 Superkine platforms. In addition, Medicenna continued to pursue strategic partnering for bizaxofusp and strengthened its balance sheet through a public offering of units and a structured financing arrangement, while also adding Dr. Nageatte Ibrahim as fractional chief medical officer to support its development strategy.
Company News
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Medicenna Announces the Launch of a Marketed Public Offering of Securities
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
Medicenna Therapeutics Announces Participation in Upcoming Conferences
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Medicenna Announces Changes to Board Composition
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy Transcript
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025